Related Experiment Videos
Neuroprotective gene therapy for Parkinson's disease
L Tenenbaum1, A Chtarto, E Lehtonen
1Laboratory of Experimental Neurosurgery, Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, Hĵpital Erasme, 808, Route de Lennik, B-1070 Brussels, Belgium,. litenenb@ulb.ac.be
Current Gene Therapy
|December 13, 2002
Summary
Gene therapy offers neuroprotection for Parkinson's disease (PD) by delivering protective factors directly to the brain. This approach aims to prevent neuronal cell death and dysfunction, offering a promising avenue for treatment.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Parkinson's disease (PD) involves progressive loss of dopaminergic neurons, with apoptosis contributing significantly to cell death.
- Excitotoxicity, oxidative stress, and mitochondrial dysfunction are key apoptosis inducers in PD.
- The blood-brain barrier limits systemic delivery of neuroprotective agents.
Purpose of the Study:
- To explore gene therapy as a neuroprotective strategy for Parkinson's disease.
- To investigate in situ and ex vivo gene delivery methods for sustained local administration of protective factors.
- To address challenges and safety concerns associated with gene transfer in the central nervous system.
Main Methods:
- Utilizing viral vectors for stable gene expression in the central nervous system.
- Employing ex vivo gene delivery combined with cell replacement therapies.
- Evaluating gene therapy strategies in various animal models of Parkinson's disease, including toxin-induced and transgenic models.
Main Results:
- Demonstrated efficacy of viral vectors in animal models for both ex vivo and in vivo applications.
- Potential for gene therapy to provide neuroprotection to grafted cells and host neurons.
- Identification of safety concerns including diffusion, axonal transport, integration, and immune responses.
Conclusions:
- In situ gene delivery is a viable strategy for local and sustained administration of neuroprotective factors in PD.
- Combining ex vivo gene delivery with cell transplantation offers dual neuroprotection.
- Further development of viral and non-viral vectors, alongside controlled gene expression elements, is crucial for safe and effective gene therapy in Parkinson's disease.